Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: GENFIT

Market Cap 472M 0 548M 435M 408M 766M 51.79B 774M 5.14B 2B 25.36B 2.06B 2.01B 87.89B P/E Ratio 2025
-3.06x
P/E Ratio 2026 * 49.9x
Enterprise Value 417M 0 484M 384M 361M 677M 45.79B 685M 4.54B 1.77B 22.42B 1.82B 1.78B 77.7B EV / Sales 2025
2.34x
EV / Sales 2026 * 4.47x
Free-Float
86.88%
Yield 2025 *
-
Yield 2026 * -
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%-1.16%-11.90%-10.16% 43.51B
-2.17%+4.70%+293.71%+535.99% 33.29B
-1.60%-1.58%-0.19%+31.82% 29.34B
+0.44%-3.80%+12.51%-17.06% 29.9B
-0.29%+2.65%+13.24%+21.04% 25.42B
+3.54%+8.43% - - 14.36B
-1.26%-1.11%+53.37%+108.10% 13.18B
-1.12%-5.23%+2.24%+3.33% 12.72B
-1.18%-2.00%+107.41%+78.18% 12.08B
Average -0.42%+0.59%+58.80%+93.90% 23.76B
Weighted average by Cap. -0.53%+0.64%+60.14%+104.14%

Financials

2025 2026 *
Net sales 66.82M 0 77.53M 61.53M 57.77M 108M 7.33B 110M 727M 283M 3.59B 291M 285M 12.44B 95.2M 0 110M 87.66M 82.31M 155M 10.44B 156M 1.04B 404M 5.11B 415M 406M 17.72B
Net income -8.3M -0 -9.63M -7.65M -7.18M -13.48M -911M -13.62M -90.34M -35.19M -446M -36.15M -35.39M -1.55B 18.31M 0 21.24M 16.86M 15.83M 29.72M 2.01B 30.03M 199M 77.6M 983M 79.72M 78.02M 3.41B
Net Debt -54.72M -0 -63.49M -50.39M -47.31M -88.82M -6B -89.76M -595M -232M -2.94B -238M -233M -10.19B -46.87M -0 -54.38M -43.16M -40.52M -76.08M -5.14B -76.88M -510M -199M -2.52B -204M -200M -8.73B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!